Literature DB >> 10515967

Nociceptin augments K(+) currents in hippocampal CA1 neurons by both ORL-1 and opiate receptor mechanisms.

S G Madamba1, P Schweitzer, G R Siggins.   

Abstract

We previously reported (see also the accompanying paper) that dynorphin A significantly enhanced the voltage-dependent K(+) M-current (I(M)) in CA3 and CA1 hippocampal pyramidal neurons (HPNs). Because the opioid-receptor-like-1 (ORL-1) receptor shares a high sequence homology with opioid receptors and is expressed in rat hippocampus, we examined the effects of orphanin FQ or nociceptin, the endogenous ligand for the ORL-1 receptor, using the rat hippocampal slice preparation and intracellular voltage-clamp recording. Current-voltage (I-V) relationships from CA1 HPNs revealed that nociceptin superfusion induced an outward current reversing near the equilibrium potential for K(+) ions. Ba(2+) (2 mM) blocked this effect. The nociceptin-induced current was largest at depolarized membrane potentials, where I(M) is largely activated. Nociceptin concentrations of 0.5-1 microM (but not 0.1 microM) significantly increased I(M) relaxation amplitudes with recovery on washout. Interestingly, both the general opiate antagonist naloxone and the kappa receptor antagonist nor-binaltorphimine (nBNI) inhibited the nociceptin-induced I(M) increases and outward currents in the depolarized range but not the inward current induced at hyperpolarized potentials. The putative ORL-1 receptor antagonist, [Phe(1)Psi(CH(2)-NH)Gly(2)]NC(1-13)NH(2) (hereafter ORLAn), blocked most of the nociceptin current near rest but not the I(M) increase. However, ORLAn alone had direct effects similar to those of nociceptin, indicating that ORLAn might be a partial agonist. Our results suggest that nociceptin postsynaptically modulates the excitability of HPNs through ORL-1 and kappa-like opiate receptors linked to different K(+) channels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515967     DOI: 10.1152/jn.1999.82.4.1776

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  8 in total

1.  Nociceptin reduces epileptiform events in CA3 hippocampus via presynaptic and postsynaptic mechanisms.

Authors:  M K Tallent; S G Madamba; G R Siggins
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

2.  Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala.

Authors:  Marisa Roberto; George R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-20       Impact factor: 11.205

3.  Inhibitory action of nociceptin/orphanin FQ on functionally different thalamic neurons in urethane-anaesthetized rats.

Authors:  D Albrecht; R Blühdorn; H Siegmund; H Berger; G Calo'
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 4.  Synaptic effects induced by alcohol.

Authors:  David M Lovinger; Marisa Roberto
Journal:  Curr Top Behav Neurosci       Date:  2013

5.  Roles of K+ and cation channels in ORL-1 receptor-mediated depression of neuronal excitability and epileptic activities in the medial entorhinal cortex.

Authors:  Huiming Li; Binqi Hu; Hao-Peng Zhang; Cody A Boyle; Saobo Lei
Journal:  Neuropharmacology       Date:  2019-04-15       Impact factor: 5.250

6.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 7.  Somatostatin: an endogenous antiepileptic.

Authors:  Melanie K Tallent; Cuie Qiu
Journal:  Mol Cell Endocrinol       Date:  2007-12-14       Impact factor: 4.102

8.  Enhancing m currents: a way out for neuropathic pain?

Authors:  Ivan Rivera-Arconada; Carolina Roza; Jose A Lopez-Garcia
Journal:  Front Mol Neurosci       Date:  2009-08-04       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.